3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Lung Neoplasms
3
Mesothelioma, Malignant
2
Carcinoma, Non-Small-Cell Lung
2
Small Cell Lung Carcinoma
1
Non-small Cell Lung Cancer Metastatic
1
Mesothelioma
1
Interventions
Pemetrexed
40
Cisplatin
35
pembrolizumab
21
Nivolumab
17
Carboplatin
16
Ipilimumab
13
Gemcitabine
10
Cyclophosphamide
9
fludarabine
6
durvalumab
6
Bevacizumab
6
Radiotherapy, Intensity-Modulated
4
LMB-100
4
Drug Therapy
4
Dexamethasone
4
tremelimumab
3
tazemetostat
3
spartalizumab
3
olaparib
3
niraparib
3
atezolizumab
3
anetumab ravtansine
3
amatuximab
3
Vinorelbine
3
Paclitaxel
3
Oxaliplatin
3
Imatinib Mesylate
3
Fluorouracil
3
Cerebral Decortication
3
Blood Specimen Collection
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma
×
Data Collection
×
Thoracic
×
Clear all
NCT05308966
2025-10-06
MESO-IMMUNE
Groupe Francais De Pneumo-Cancerologie
Completed
204 enrolled